Table 2. Distribution of induction regimens, consolidative transplants, maintenance therapy, and treatment responses.
|
Number of patients (%) |
||
|
53 |
||
|
Induction treatment, n (%) |
Only PI-based |
29 (54.7) |
|
Only IMID-based |
2 (3.7) |
|
|
PI- and IMID-based |
8 (15.1) |
|
|
PI and/or IMIDs + PACE |
9 (16.9) |
|
|
*Only VAD |
5 (9.4) |
|
|
Response to induction therapy, n (%) |
CR/VGPR |
8 (15.1)/13 (24.5) |
|
PR/MR |
7 (13.2)/5 (9.4) |
|
|
SD/progression |
6 (11.3)/3 (5.7) |
|
|
Unspecified |
11 (20.8) |
|
|
HSCT, n (%) |
Yes (autologous/allogeneic) |
21 (20/1) (39.6) |
|
No |
32 (60.4) |
|
|
Maintenance, n (%) |
13 (24.5) |
|
|
Lenalidomide |
7 (13.2) |
|
|
Bortezomib |
3 (5.6) |
|
|
PI and IMID combination |
3 (5.6) |
|
|
Final status after first-line treatment, n (%) |
51 |
|
|
Refractory |
22 (41.5) |
|
|
Relapse |
20 (37.7) |
|
|
Remission |
9 (16.9) |
CR: Complete response; HSCT: hematopoietic stem cell transplantation; IMID: immunomodulatory agent; MR: minimal response; PACE: cisplatin, doxorubicin, cyclophosphamide, etoposide; PI: proteasome inhibitor; PR: partial response; SD: stable disease; VAD: vincristine, adriamycin, dexamethasone; VGPR: very good partial response.
Only PI-based: VD: Bortezomib, dexamethasone; VCD: bortezomib, cyclophosphamide, dexamethasone. Only IMID-based: MPT: Melphalan, prednisone, thalidomide.
PI- and IMID-based: VRD: Bortezomib, lenalidomide, dexamethasone; VTD: bortezomib, thalidomide, dexamethasone. PI and/or IMIDs + PACE: VCD or VTD + PACE.
*: PI (bortezomib) and/or IMIDs (lenalidomide and thalidomide) were used in the subsequent treatment processes of the patients.